Compare Monolithic Power Systems Inc (MPWR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Moderna, Inc. — how do they compare? Monolithic Power Systems Inc trades at $1,204.39 (market cap $59.88B), while Moderna, Inc. trades at $136.15 (market cap $56.02B). The key difference: Monolithic Power Systems Inc and Moderna, Inc. are close in size by market cap, and Monolithic Power Systems Inc pays a 0.66% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MPWR | MRNA | |
|---|---|---|
Market Cap | $59.88B | $56.02B |
Sector | Utilities | Health |
52-Week High | $1.69K | $174.38 |
52-Week Low | $834.14 | $22.36 |
Enterprise Value | $58.49B | $52.17B |
Dividend Yield | 0.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,218.50, down 0.44% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $6.50 beating expectations of $5.87, driven by AI infrastructure demand. Valuation remains elevated with a P/E of 74.34 and P/S of 18.21, while profitability metrics show robust net income margin of 24.5% and ROE of 21.98%.
The stock faces near-term technical pressure but maintains strong fundamental growth prospects from AI and server demand. Analyst consensus remains overwhelmingly bullish with 88% buy ratings and a $1,860 price target representing 53% upside. Key risks include premium valuation concerns and potential double-ordering in enterprise data segments.
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
